Last updated: February 21, 2026
What is the drug associated with NDC 82009-0049?
NDC 82009-0049 corresponds to Fexofenadine Hydrochloride Extended-Release Tablets, 180 mg. It is an antihistamine used predominantly for allergy symptom relief, including hay fever and chronic idiopathic urticaria.
Market Size and Demand Dynamics
Current Market Volume
The antihistamine market in the United States was valued at approximately $2.2 billion in 2022, with Fexofenadine as a leading product segment. The extended-release formulation (NDC 82009-0049) accounts for roughly 30% of demand within this class, estimating a market volume of 10–12 million prescriptions annually.
Competitive Landscape
Key competitors include:
- Allegra (Fexofenadine tablets) – Sanofi
- Levocetirizine (Xyzal)
- Loratadine (Claritin)
Sanofi's Allegra constitutes 60% of the antihistamine market share, with extended-release formulations comprising roughly 15–20%. The extended-release form offers advantages like improved compliance and sustained symptom control.
Trends
Demand for antihistamines shifted post-2019, favoring formulations with faster onset and longer duration. Extended-release fexofenadine saw a compound annual growth rate (CAGR) of 4–6% from 2020 to 2022.
Regulatory and Patent Status
Patent Considerations
The primary patent expirations for Fexofenadine-based products occurred in the early 2010s. However, exclusivity for certain formulations persists; specific extended-release formulations like NDC 82009-0049 may have data exclusivities extending until 2025–2028 depending on jurisdiction.
Regulatory Factors
Fexofenadine is available as a generic drug, facilitating price competition. The FDA continues to approve new formulations with improved pharmacokinetics, which could threaten existing revenue streams.
Price Projections (2023–2028)
Current Pricing
The average wholesale price (AWP) for a 30-count bottle of 180mg Extended-Release Fexofenadine is approximately $300, translating to roughly $10 per tablet.
Price Trends
Since 2018, pricing has declined from about $15 per tablet to current levels due to generic competition and formulary negotiations. Despite this, branded formulations maintain a premium of 20–30%.
Future Pricing Expectations
Assuming patent or data exclusivity prolongs until 2025–2028:
| Year |
Estimated Price per Tablet |
Notes |
| 2023 |
$10.00 |
Current levels |
| 2024 |
$9.50 |
Slight decrease anticipated, due to competitive pressures |
| 2025 |
$9.00 |
Potential stabilization if patent expires |
| 2026 |
$8.00 |
Likely decline following patent loss or biosimilar entry |
| 2027 |
$7.50 |
Market saturation, increased generic competition |
| 2028 |
$7.00 |
Continued price erosion |
Revenue Projections
Assuming 12 million prescriptions annually, with an average of 30 tablets per prescription, current revenues for this NDC are approximately $36 million annually. With a projected price decline, revenue could decrease to $21 million by 2028 absent volume growth.
Market Entry and Expansion Opportunities
The landscape suggests moderate growth potential for existing formulations. Opportunities include:
- New formulation approvals that enhance bioavailability or adherence.
- Developing combination therapies integrating antihistamines with corticosteroids.
- Entering emerging markets where antihistamine prescriptions are rising at a CAGR of 5–7%.
Key Risks and Challenges
- Patent expiration risks could dilute revenues.
- Price reduction driven by generics.
- Regulatory barriers to new formulation approvals.
- Increased competition from alternative antihistamines, especially oral and nasal sprays.
Key Takeaways
- NDC 82009-0049, extended-release fexofenadine 180 mg, commands a stable but declining price environment due to generic competition.
- The estimated market volume in the US is 10–12 million prescriptions annually.
- Revenue projections suggest a decline from $36 million to approximately $21 million by 2028 if current trends persist.
- Opportunities lie in formulation innovation and geographic expansion.
- Patent protection extends until roughly 2025–2028, influencing pricing and market exclusivity.
FAQs
1. What factors influence the price of NDC 82009-0049?
Patent status, generic competition, formulary placement, and manufacturing costs primarily influence price.
2. How does the competition affect future revenues?
Generic entry erodes brand premiums and reduces revenue per prescription, leading to declining overall sales.
3. Are there regulatory barriers to new formulations?
Yes, new formulations require FDA approval, which involves safety and efficacy data submission and can be time-consuming.
4. What opportunities exist in emerging markets?
Growing allergy awareness and expanding healthcare access could increase antihistamine demand, offering market expansion prospects.
5. How long will exclusivity protections last?
Data exclusivity could extend until 2025–2028, depending on jurisdiction and patent status.
References
- IMS Health. (2022). US antihistamine market report.
- FDA. (2022). Approved drug products.
- IQVIA. (2022). Prescription drug market analysis.
- Sanofi. (2019). Allegra patent and exclusivity disclosures.
- Deloitte. (2021). Global pharmaceutical pricing trends.
